Regulatory T-cell Genes Drive Altered Immune Microenvironment in Adult Solid Cancers and Allow for Immune Contextual Patient Subtyping

Background: The tumor microenvironment is an important factor in cancer immunotherapy response. To further understand how a tumor affects the local immune system, we analyzed immune gene expression differences between matching normal and tumor tissue. Methods: We analyzed public and new gene expression data from solid cancers and isolated immune cell populations. We also determined the correlation between CD8, FoxP3 IHC, and our gene signatures. Results: We observed that regulatory T cells (Tregs) were one of the main drivers of immune gene expression differences between normal and tumor tissue. A tumor-specific CD8 signature was slightly lower in tumor tissue compared with normal of most (12 of 16) cancers, whereas a Treg signature was higher in tumor tissue of all cancers except liver. Clustering by Treg signature found two groups in colorectal cancer datasets. The high Treg cluster had more samples that were consensus molecular subtype 1/4, right-sided, and microsatellite-instable, compared with the low Treg cluster. Finally, we found that the correlation between signature and IHC was low in our small dataset, but samples in the high Treg cluster had significantly more CD8+ and FoxP3+ cells compared with the low Treg cluster. Conclusions: Treg gene expression is highly indicative of the overall tumor immune environment. Impact: In comparison with the consensus molecular subtype and microsatellite status, the Treg signature identifies more colorectal tumors with high immune activation that may benefit from cancer immunotherapy. Cancer Epidemiol Biomarkers Prev; 27(1); 103–12. ©2017 AACR.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[3]  J. Collins,et al.  Large-Scale Mapping and Validation of Escherichia coli Transcriptional Regulation from a Compendium of Expression Profiles , 2007, PLoS biology.

[4]  Gianluca Bontempi,et al.  minet: A R/Bioconductor Package for Inferring Large Transcriptional Networks Using Mutual Information , 2008, BMC Bioinformatics.

[5]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[6]  Lin Zhang,et al.  Tissue-based immune monitoring I , 2011, Cancer biology & therapy.

[7]  Zoltan Szallasi,et al.  Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.

[8]  R. Nussenblatt,et al.  Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[9]  T. Gajewski,et al.  Rational combinations of immunotherapeutics that target discrete pathways , 2013, Journal of Immunotherapy for Cancer.

[10]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[11]  C. Hennig,et al.  How to find an appropriate clustering for mixed‐type variables with application to socio‐economic stratification , 2013 .

[12]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[13]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[14]  A. Cribbs,et al.  A novel upstream enhancer of FOXP3, sensitive to methylation‐induced silencing, exhibits dysregulated methylation in rheumatoid arthritis Treg cells , 2014, European journal of immunology.

[15]  J. Galon,et al.  The immune landscape of human tumors , 2014, Oncoimmunology.

[16]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[17]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[18]  D. Chaussabel,et al.  The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types , 2015, PloS one.

[19]  V. Kristensen,et al.  Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells , 2015, Molecular oncology.

[20]  Noriaki Ohuchi,et al.  Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study , 2015, Breast Cancer Research.

[21]  S. Takai,et al.  Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans , 2015, The Journal of Immunology.

[22]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Pircher,et al.  Treg(s) in Cancer: Friends or Foe? , 2015, Journal of cellular physiology.

[24]  A. Rudensky,et al.  A Distinct Function of Regulatory T Cells in Tissue Protection , 2015, Cell.

[25]  Pornpimol Charoentong,et al.  Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.

[26]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[27]  Etienne Becht,et al.  Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.

[28]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[29]  Ash A. Alizadeh,et al.  High-throughput genomic profiling of tumor-infiltrating leukocytes. , 2016, Current opinion in immunology.

[30]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[31]  Solomon F. Brown,et al.  Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives , 2016, Front. Immunol..

[32]  Michael R. Speicher,et al.  The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis , 2016, Science Translational Medicine.

[33]  M. Hattori,et al.  Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.

[34]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[35]  A. Butte,et al.  Cross-tissue Analysis of Gene and Protein Expression in Normal and Cancer Tissues , 2016, Scientific Reports.

[36]  G. Plitas,et al.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.

[37]  S. Chanock,et al.  Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. , 2016, Cancer research.

[38]  Elisa Ficarra,et al.  Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.